PK/PD modelling : Clinical Implications

J. Mouton, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

7th ISAP Pharmacokinetics / Pharmacodynamics (PK / PD) Educational Workshop
San Diego, CA. September 26th, 2001

Click here to start

Table of Contents

Pk/Pd modelling :Clinical Implications

infections are treated with the same

AUIC =125 : a magical number??

Example Target Controlled DosingIxacin

Use of Pharmacodynamics in setting breakpoints

Pharmacodynamics of fluoroquinolones against Pseudomonas infection in neutropenic ratsDrusano et.al., AAC, 1993, 37: 483-90.

T>MIC: how long??breakpoints

Same all beta-lactams?Same all m.o.?

Monte Carlo Simulations in pk/pd (1)

Target Attainment Rates

Monte Carlo Simulations in pk/pd (2)

Cumulative Fraction of Response

Pharmacodynamic properties of beta-lactams

Target Concentrationcontinuous infusion

Continuous InfusionPharmacokinetic Considerations

Dose Calculationscontinuous infusion

Example Target Controlled Dosingcefticostix

Therapeutic Drug Monitoringcontinuous infusion

Ceftazidime concentrationsICU patients

Piperacillin concentrationscontinuous vs intermittent

Author: Johan Mouton

Email: webmaster@isap.org

Home Page: http://www.isap.org/slides.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of ISAP. Send your requests to <webmaster@isap.org>

Download presentation as PDF file